OOIR: Observatory of International Research

Papers

(The TQCC of npj Precision Oncology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Machine learning approaches to drug response prediction: challenges and recent progress	165
3D bioprinting for reconstituting the cancer microenvironment	158
Classification and mutation prediction based on histopathology H&E images in liver cancer using deep learning	118
Patient-derived organoids as a predictive biomarker for treatment response in cancer patients	116
Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer	82
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population	80
High expression of ACE2 and TMPRSS2 and clinical characteristics of COVID-19 in colorectal cancer patients	63
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma	55
Microbiome dysbiosis in lung cancer: from composition to therapy	54
Multiplex bioimaging of single-cell spatial profiles for precision cancer diagnostics and therapeutics	53
Quantitative MRI-based radiomics for noninvasively predicting molecular subtypes and survival in glioma patients	53
Blood-derived lncRNAs as biomarkers for cancer diagnosis: the Good, the Bad and the Beauty	52
Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy	48
Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity	48
Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance	45
GD2 CAR T cells against human glioblastoma	45
The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response	42
Multiplexed drug testing of tumor slices using a microfluidic platform	38
Will polygenic risk scores for cancer ever be clinically useful?	37
Genetic mutation and biological pathway prediction based on whole slide images in breast carcinoma using deep learning	36
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes	34
Clinical application of a lung cancer organoid (tumoroid) culture system	34
Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition	33
High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition	30
Dynamic roles of inflammasomes in inflammatory tumor microenvironment	30

Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets	30
The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib	30
Deep learning for end-to-end kidney cancer diagnosis on multi-phase abdominal computed tomography	29
Structural variant detection in cancer genomes: computational challenges and perspectives for precision oncology	29
A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients	29
Survival improvement for patients with metastatic colorectal cancer over twenty years	27
Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer	26
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer	26
A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors	26
Identification of gastric cancer subtypes based on pathway clustering	26
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors	25
Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy	25
Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes	25
Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient	25
Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)	24
Antibody-drug conjugates in lung cancer: dawn of a new era?	24
A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy	24
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis	23
Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients	23
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer	23
Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma	22
Co-occurring genomic alterations and immunotherapy efficacy in NSCLC	22
Cell graph neural networks enable the precise prediction of patient survival in gastric cancer	22
Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA	21
Targeting CDK1 in cancer: mechanisms and implications	21
Just Add Data: automated predictive modeling for knowledge discovery and feature selection	21
Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome	21
A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer	20
Self-supervised attention-based deep learning for pan-cancer mutation prediction from histopathology	20
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer	20
Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review	20
A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer	20
Artificial intelligence reveals features associated with breast cancer neoadjuvant chemotherapy responses from multi-stain histopathologic images	20
Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance	20
Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma	20
The identification and functional analysis of CD8+PD-1+CD161+ T cells in hepatocellular carcinoma	19
Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma	19
A deep learning model for molecular label transfer that enables cancer cell identification from histopathology images	19
Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury	19
Plasma cell-free RNA profiling distinguishes cancers from pre-malignant conditions in solid and hematologic malignancies	19
Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor	19
Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells	19
Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas	19
Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade	19
Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma	18
Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia	18
Prostate cancer polygenic risk score and prediction of lethal prostate cancer	18
Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade	18
Association of mismatch repair status with survival and response to neoadjuvant chemo(radio)therapy in rectal cancer	18
Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets	18

Vaginal microbiota, genital inflammation, and neoplasia impact immune checkpoint protein profiles in the cervicovaginal microenvironment	18
Mendelian randomization analyses of genetically predicted circulating levels of cytokines with risk of breast cancer	17
Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics	17
Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features	17
Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis	17
Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns	17
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial	17
A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures	17
Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients	16
Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition	16
Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer	16
Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions	16
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy	16
Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors	16
Spatially variant immune infiltration scoring in human cancer tissues	16
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma	16
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?	16
Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups	16
Rare deleterious germline variants and risk of lung cancer	15
Usability of deep learning and H&E images predict disease outcome-emerging tool to optimize clinical trials	15
Artificial intelligence for the next generation of precision oncology	15
Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma	15
Acetylation of ELF5 suppresses breast cancer progression by promoting its degradation and targeting CCND1	15
Association of pro-inflammatory soluble cytokine receptors early during hepatocellular carcinoma stereotactic radiotherapy with liver toxicity	15
The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia	15
Progression of prostate carcinoma is promoted by adipose stromal cell-secreted CXCL12 signaling in prostate epithelium	15
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial	15
Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma	15
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance	15
Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types	14
Imaging immunity in patients with cancer using positron emission tomography	14
On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer	14
Combined low-pass whole genome and targeted sequencing in liquid biopsies for pediatric solid tumors	13
Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study	13
Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations	13
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features	13
Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations	13
Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia	13
Circulating stromal cells in resectable pancreatic cancer correlates to pathological stage and predicts for poor clinical outcomes	13
Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma	13
Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance	13